You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

recurrent cervical cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cervical Cancer Recurrent Trial in Beijing (RC48 + Tislelizumab)

Recruiting
  • Cervical Cancer Recurrent
  • RC48 + Tislelizumab
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Sep 25, 2023

Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical

Recruiting
  • Cervical Cancer
  • +2 more
  • Treatment Group
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
May 9, 2023

Advanced Cancer, Metastatic Cervical Cancer Trial in Albuquerque, Yerevan (Balstilimab (BAL), Topotecan, Vinorelbine)

Withdrawn
  • Advanced Cancer
  • Metastatic Cervical Cancer
  • Balstilimab (BAL)
  • +5 more
  • Albuquerque, New Mexico
  • +2 more
Oct 3, 2022

Recurrent Cervical Cancer Trial in Guangzhou (anti-PD-1+Albumin-Bound Paclitaxel)

Active, not recruiting
  • Recurrent Cervical Cancer
  • anti-PD-1+Albumin-Bound Paclitaxel
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 26, 2022

Cadonilimab in Recurrent or Metastatic Cervical Cancer

Not yet recruiting
  • Recurrent or Metastatic Cervical Cancer
  • (no location specified)
Nov 23, 2023

Cervical Cancer Trial in Hidaka (Pembrolizumab, Olaparib)

Active, not recruiting
  • Cervical Cancer
  • Hidaka, Saitama, Japan
    Saitama Medical Uiversity International Medical Center
Aug 8, 2022

Cervical Cancer Trial (Nimotuzumab?Tislelizumab)

Not yet recruiting
  • Cervical Cancer
  • (no location specified)
Sep 9, 2023

Cervical Cancer, Recurrent Cervical Cancer, Metastatic Cervical Cancer Trial in Mobile (Cabozantinib 40 MG oral once a day,

Terminated
  • Cervical Cancer
  • +3 more
  • Cabozantinib 40 MG oral once a day
  • Pembrolizumab 200 mg IV every 3 weeks
  • Mobile, Alabama
    University of South Alabama Mitchell Cancer Institute
Jun 3, 2022

AK104 Combined With I-125 Brachytherapy for Recurrent or

Not yet recruiting
  • Cervical Cancer
  • Iodine-125 particle brachytherapy
  • AK104
  • (no location specified)
Sep 25, 2023

Cervical Cancer Trial in Hong Kong (Avelumab, Axitinib)

Recruiting
  • Cervical Cancer
  • Hong Kong, Hong Kong
    The University of Hong Kong
Feb 23, 2022

Targeted Therapy, Chemo, Recurrent Cervical Carcinoma Trial in Beijing (Donafenib combined with paclitaxel and platinum ± PD-1

Recruiting
  • Targeted Therapy
  • +6 more
  • Donafenib combined with paclitaxel and platinum ± PD-1 antibody
  • Beijing, Beijing, China
    Lei Li
Mar 26, 2022

Cervical Cancer Trial (Sacituzumab Govitecan)

Not yet recruiting
  • Cervical Cancer
  • Sacituzumab Govitecan
  • (no location specified)
Apr 18, 2023

Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy Trial run by the Precigen, Inc (PRGN-2009 plus Pembrolizumab,

Not yet recruiting
  • Cervical Cancer
  • +2 more
  • PRGN-2009 plus Pembrolizumab
  • Pembrolizumab alone
  • Bethesda, Maryland
    National Institute of Health
Nov 27, 2023

Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma, Persistent Cervical Carcinoma Trial in Beijing (Tislelizumab plus

Recruiting
  • Recurrent Cervical Carcinoma
  • +9 more
  • Tislelizumab plus radiotherapy
  • Beijing, Beijing, China
    Lei Li
Apr 1, 2022

Uterine Cervical Tumors, Cancer of Cervix, Cervical Cancer Trial (Cadonilimab, Nab paclitaxel)

Not yet recruiting
  • Uterine Cervical Neoplasms
  • +5 more
  • (no location specified)
Apr 9, 2023

Uterine Cervical Tumors, Oncolytic Virotherapy, Camrelizumab Trial in China (Recombinant human adenovirus type 5+Camrelizumab)

Not yet recruiting
  • Uterine Cervical Neoplasms
  • +2 more
  • Recombinant human adenovirus type 5＋Camrelizumab
  • Hangzhou, Zhejiang, China
  • +3 more
Feb 8, 2022

Persistent, Recurrent, or Metastatic Cervical Cancer Trial in Shanghai (GLS-010, Placebo, paclitaxel)

Not yet recruiting
  • Persistent, Recurrent, or Metastatic Cervical Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Hospital
Apr 4, 2023

Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (Chemotherapy plus apatinib)

Completed
  • Recurrent Cervical Carcinoma
  • +5 more
  • Chemotherapy plus apatinib
  • Beijing, Beijing, China
    Lei Li
Mar 12, 2022

PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer

Recruiting
  • Immune Checkpoint Inhibitors
  • +9 more
  • Radiotherapy for targeted lesions and PD-1 antibody
  • Beijing, Beijing, China
    Lei Li
Apr 1, 2022

Uterine Cervical Tumors Trial in Wuhan (BS-006)

Not yet recruiting
  • Uterine Cervical Neoplasms
  • BS-006
  • Wuhan, Hubei, China
    Zhongnan Hospital of Wuhan University
Jun 6, 2022

Retrospective Cervical Cancer Oligo States Multicentre Outcomes

Not yet recruiting
  • Cancer, Cervical
  • +2 more
  • Concurrent Chemoradiation, Systemic Chemotherapy other locally directed therapies (like surgery, ablation, etc.)
  • (no location specified)
Nov 28, 2023

Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (A combination of anti-PD-1

Completed
  • Recurrent Cervical Carcinoma
  • +4 more
  • A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel
  • Beijing, Beijing, China
    Lei Li
Mar 12, 2022

Cervical Cancer Trial in Beijing (BL-B01D1, SI-B003)

Not yet recruiting
  • Cervical Cancer
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Aug 16, 2023

Metastatic Cervical Cancer Trial (Tislelizumab, Sitravatinib)

Not yet recruiting
  • Metastatic Cervical Cancer
  • (no location specified)
Jan 31, 2023

Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (Anti-PD-1 antibody camrelizumab,

Recruiting
  • Recurrent Cervical Carcinoma
  • +5 more
  • Anti-PD-1 antibody camrelizumab
  • Albumin-bound paclitaxel
  • Beijing, Beijing, China
    Lei Li
Mar 12, 2022